Cell Therapy Market By Novartis AG; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Services, Inc

The global Cell Therapy Market size is expected to reach USD 15.89 billion by 2030, expanding at 16.50% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The market players are witnessing an increasing interest in the development of advanced therapies that are based on tissue, gene, or cell. Research communities and companies continue to make large investments in the culturing and isolation of a broad range of cell types, such as keratinocytes, chondrocytes, cartilage, stem, dermal papilla, & epithelial cells for the development of novel therapies.

Regulatory authorities such as FDA play a crucial role in the growth of the market by undertaking initiatives related to the development and approval of advanced treatment development as well as restriction of unregulated treatments. In addition, direct cellular reprogramming is attracting interest as a cutting-edge treatment approach because of its advantages such as efficacy and security.

On the other hand, an increase in the number of clinical trials related to advanced therapies is expected to boost the market growth in the coming years. According to data obtained from the American Society of Gene & Cell Therapy, in Q1 2022, 32 non-genetically modified cellular therapy trials were initiated, and 69% of these were in the non-oncology arena. Moreover, according to ClinicalTrials.gov, more than 1800 active cellular therapies are under clinical trial.

Furthermore, key companies operating in the market are undertaking several strategic initiatives such as various agreements, new launches, and expansion to strengthen their market presence. For instance, in May 2022, the University of Pennsylvania's personalized cellular therapy was approved for the treatment of individuals with relapsed or resistant follicular lymphoma.

Moreover, in April 2021, Bristol Myers Squibb declared that U.S. FDA approved its Breyanzi (lisocabtagene maraleucel), a novel CAR T treatment for adults with R/R large B-cell lymphoma. In the pivotal trial for 3L+ LBCL, TRANSCEND NHL 001, Breyanzi showed a 73% overall response rate and a 54% complete response (CR) rate.

Related Press Release@ Cell Therapy Market Report

Cell Therapy Market Report Highlights

  • Autologous therapy segment dominated the market with the largest revenue share of 94.64% owing to increasing adoption of this therapy type coupled with lower risk of life-threatening complications
  • Allogenic therapy segment is expected to grow significantly in the coming years owing to factors such as high pricing and growth in stem cell banking. Moreover, many companies are preparing to shift their business toward allogenic cell therapy product development
  • Oncology therapeutic area captured the largest market share of 38.23% in 2022 owing to the increasing adoption of advanced cell therapies in the treatment of various types of cancers. Oncology segment is also projected to exhibit the fastest growth rate of 14.95% during the forecast years
  • Cell therapy are also under the investigation for musculoskeletal disorders and has great potential for market growth
  • North America dominated the global cell therapy market owing to the strong regulatory framework, presence of bodies like the International Society for Cellular Therapy, and presence of key operating companies

Cell Therapy Market Segmentation

Grand View Research has segmented the global cell therapy market based on therapy type, therapeutic area, and region:

Therapy Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Allogeneic Therapies
    • Stem Cell Therapies
      • Hematopoietic Stem Cell Therapies
      • Mesenchymal Stem Cell Therapies
    • Non-Stem Cell Therapies
      • Keratinocytes & Fibroblast-based Therapies
      • Others
  • Autologous Therapies
    • Stem Cell Therapies
      • BM, Blood, & Umbilical Cord-derived Stem Cells
      • Adipose derived cells
      • Others
    • Non-Stem Cell Therapies
      • T-Cell Therapies
    • CAR T Cell Therapy
    • T Cell Receptor (TCR)-based
  • Others

Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology
  • Cardiovascular Disease (CVD)
  • Musculoskeletal Disorders
  • Dermatology
  • Others

Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • Switzerland
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
  • Rest of the World

List of Key Players in the Cell Therapy Market

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Tego Science
  • Atara Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio, Inc.
  • Dendreon Corp.

Views: 8


You need to be a member of On Feet Nation to add comments!

Join On Feet Nation

© 2023   Created by PH the vintage.   Powered by

Badges  |  Report an Issue  |  Terms of Service